Busca un médico

Kebede H. Begna, M.D.

  1. Hematologist
  2. Internist
Solicite una Consulta

Publicaciones

  1. Csizmar CM, Saliba AN, Greipp PT, Alkhateeb H, Begna KH, Foran JM, Gangat N, Hogan WJ, Hook CC, Litzow MR, Mangaonkar AA, Palmer JM, Pardanani A, Shah MV, Tefferi A, Torghabeh MH, Wolanskyj-Spinner AP, Patnaik MM, Kaufmann SH, Al-Kali A. FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): the Mayo Clinic experience. Haematologica. 2024 Nov 1; 109 (11):3785-3789 Epub 2024 Nov 01
    View PubMed
  2. Katamesh B, Nanaa A, He R, Viswanatha D, Greipp PT, Bessonen K, Nguyen P, Jevremovic D, Yi CA, Foran J, Begna K, Gangat N, Mangaonkar A, Saliba AN, Patnaik MM, Hogan WJ, Litzow M, Tefferi A, Shah MV, Alkhateeb HB, Al-Kali A. Clonal heterogeneity in STAG2m myeloid neoplasms: the Mayo Clinic experience. Ann Hematol 2024 Oct; 103 (10):4333-4336 Epub 2024 Aug 28
    View PubMed
  3. Gangat N, Singh A, Ilyas R, Loscocco GG, Elliott M, Begna K, Pardanani A, Tefferi A. Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2- and CALR-mutated essential thrombocythemia-A Mayo Clinic study of 200 pregnancies. Am J Hematol. 2024 Oct; 99 (10):1862-1869 Epub 2024 June 12
    View PubMed
  4. Baranwal A, Shah MV, Greipp P, Shi M, Reichard KK, Jevremovic D, Gangat N, Patnaik MM, Begna KH, Alkhateeb HB, Litzow MR, Hogan WJ, Tefferi A, Al-Kali A, Mangaonkar AA. Clinicopathologic correlates and prognostic impact of lymphoid aggregates in patients with myelodysplastic syndromes. Br J Haematol 2024 Oct; 205 (4):1627-1631 Epub 2024 July 31
    View PubMed
  5. Yacout M, Katamesh B, Jabban Y, He R, Viswanatha D, Jevremovic D, Greipp P, Bessonen K, Palmer J, Foran J, Saliba A, Hefazi-Torghabeh M, Begna K, Hogan W, Patnaik M, Shah M, Alkhateeb H, Al-Kali A. Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms. Leukemia. 2024 Sep 23 Epub 2024 Sept 23
    View PubMed
  6. Farrukh F, Abdelmagid M, Mangaonkar A, Patnaik M, Al-Kali A, Elliott MA, Begna KH, Hook CC, Hogan WJ, Pardanani A, Litzow MR, Ketterling RP, Gangat N, Arber DA, Orazi A, He R, Reichard K, Tefferi A. Prognostic impact of SF3B1 mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases. Haematologica. 2024 Aug 1; 109 (8):2525-2532 Epub 2024 Aug 01
    View PubMed
  7. Steinauer N, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar AA, Saliba AN, Torghabeh M, Litzow MR, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Yi CA, Tefferi A, Gangat N. Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent. Haematologica 2024 Aug 1; 109 (8):2706-2710 Epub 2024 Aug 01
    View PubMed
  8. Baranwal A, Gurney M, Basmaci R, Katamesh B, He R, Viswanatha DS, Greipp P, Foran J, Badar T, Murthy H, Yi CA, Palmer J, Mangaonkar AA, Patnaik MM, Litzow MR, Hogan WJ, Begna K, Gangat N, Tefferi A, Al-Kali A, Shah MV, Alkhateeb HB. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms. Haematologica. 2024 Jun 1; 109 (6):1779-1791 Epub 2024 June 01
    View PubMed
  9. Johnson IM, Karrar O, Rana M, Iftikhar M, Chen S, McCullough K, Saliba AN, Al-Kali A, Alkhateeb H, Begna K, Litzow M, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Hermann J, Tefferi A, Gangat N. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents. Br J Haematol. 2024 Apr; 204 (4):1232-1237 Epub 2024 Feb 04
    View PubMed
  10. Tefferi A, Fleti F, Chan O, Al Ali NH, Al-Kali A, Begna KH, Foran JM, Badar T, Khera N, Shah M, Hiwase D, Padron E, Sallman DA, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q). Br J Haematol. 2024 Apr; 204 (4):1243-1248 Epub 2023 Dec 11
    View PubMed
  11. Berman E, Shah NP, Deninger M, Altman JK, Amaya M, Begna K, Bhatia R, Chan O, Collins R, Curtin P, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore J, Oehler V, Pratz K, Pusic I, Rose M, Shomali W, Smith BD, Styler M, Sweet K, Talpaz M, Tanaka T, Tantravahi S, Tsai S, Vaughn J, Welborn J, Yang D, Mauro M, Cortes J, Radich J, Druker B. CML and the WHO: Why? J Clin Oncol. 2024 Mar 20; 42 (9):984-986 Epub 2023 Dec 12
    View PubMed
  12. Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG, Shomali W, Smith BD, Styler M, Talpaz M, Tanaka TN, Tantravahi S, Thompson J, Tsai S, Vaughn J, Welborn J, Yang DT, Sundar H, Gregory K. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 Feb; 22 (1):43-69
    View PubMed
  13. Begna KH, Abdallah NH, Janania-Martinez M, Mangaonkar AA, Rangan A, Herrick JL, Gangat N. Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant. Haematologica. 2024 Feb 1; 109 (2):689-692 Epub 2024 Feb 01
    View PubMed
  14. Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024 Feb; 99 (2):193-202 Epub 2023 Dec 10
    View PubMed
  15. Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH Jr, Curtin PT, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore JO, Oehler V, Pratz K, Pusic I, Rose MG, Shomali W, Smith BD, Styler M, Talpaz M, Tanaka TN, Tantravahi S, Thompson J, Tsai S, Vaughn J, Welborn J, Yang DT, Sundar H, Gregory K. Chronic myeloid leukemia, version 2.2024. Journal of the National Comprehensive Cancer Network. 2024 Feb; 22 (1):43-69
  16. Gangat N, Karrar O, Al-Kali A, Begna KH, Elliott MA, Wolanskyj-Spinner AP, Pardanani A, Hanson CA, Ketterling RP, Tefferi A. One thousand patients with essential thrombocythemia: the Mayo Clinic experience. Blood Cancer J. 2024 Jan 18; 14 (1):11
    View PubMed
  17. Gangat N, McCullough K, Abdelmagid M, Karrar O, Powell M, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Saliba A, Torghabeh MH, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Badar T, Foran J, Palmer J, Sproat L, Yi CA, Tefferi A. Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia. Haematologica 2024 Jan 1; 109 (1):187-292 Epub 2024 Jan 01
    View PubMed
  18. Tefferi A, Abdelmagid M, Al-Kali A, Patnaik M, Hogan WJ, Begna K, Gangat N, Orazi A, Chen D, Reichard KK, Pardanani A. Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases. Am J Hematol. 2024 Jan; 99 (1):21-27 Epub 2023 Sept 29
    View PubMed
  19. Tefferi A, Pardanani A, Al-Kali A, Alkhateeb H, McCullough K, Patnaik M, Hogan WJ, Begna K, Elliott MA, Khera N, Palmer JM, Gangat N, Kelemen K, Orazi A, Chen D, Reichard KK. Mast cell cytomorphology and treatment outcome in mast cell leukemia. Am J Hematol 2024 Jan; 99 (1):E5-E8 Epub 2023 Sept 21
    View PubMed
  20. Pardanani A, Tefferi A, Al-Kali A, Patnaik M, Hogan WJ, Begna K, Elliott MA, Khera N, Palmer JM, Gangat N, Orazi A, Kelemen K, Reichard KK, Chen D. Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome. Am J Hematol 2024 Jan; 99 (1):E1-E4 Epub 2023 Sept 09
    View PubMed
  21. Gangat N, Ilyas R, Johnson IM, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Tefferi A. Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy. Haematologica 2023 Nov 1; 108 (11):3170-3174 Epub 2023 Nov 01
    View PubMed
  22. Abdelmagid MG, Al-Kali A, Begna KH, Hogan WJ, Litzow MR, Fleti F, Mangaonkar AA, Patnaik MS, Elliott MA, Alkhateeb H, Shi M, Howard MT, Reichard KK, Ketterling RP, Shah M, Pardanani A, Gangat N, Tefferi A. Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival. Haematologica 2023 Sep 1; 108 (9):2542-2545 Epub 2023 Sept 01
    View PubMed
  23. Abdelmagid MG, Al-Kali A, Litzow MR, Begna KH, Hogan WJ, Patnaik MS, Hashmi SK, Elliott MA, Alkhateeb H, Karrar OS, Fleti F, Elnayir MH, Rivera CE, Murthy HS, Foran JM, Kharfan-Dabaja MA, Badar T, Viswanatha DS, Reichard KK, Gangat N, Tefferi A. Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events. Blood Cancer J. 2023 Aug 11; 13 (1):122
    View PubMed
  24. Gutierrez-Rodrigues F, Kusne Y, Fernandez J, Lasho T, Shalhoub R, Ma X, Alessi H, Finke C, Koster MJ, Mangaonkar A, Warrington KJ, Begna K, Xie Z, Ombrello AK, Viswanatha D, Ferrada M, Wilson L, Go R, Kourelis T, Reichard K, Olteanu H, Darden I, Hironaka D, Alemu L, Kajigaya S, Rosenzweig S, Calado RT, Groarke EM, Kastner DL, Calvo KR, Wu CO, Grayson PC, Young NS, Beck DB, Patel BA, Patnaik MM. Spectrum of clonal hematopoiesis in VEXAS syndrome. Blood. 2023 Jul 20; 142 (3):244-259
    View PubMed
  25. Gurney M, Chekkaf I, Baranwal A, Basmaci R, Katamesh B, Greipp P, Foran JM, Badar T, Mangaonkar AA, Begna KH, Gangat N, Patnaik MM, Litzow MR, Shah MV, Viswanatha DS, He R, Alkhateeb HB, Al-Kali A. The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms. Br J Haematol. 2023 Jul; 202 (2):279-283 Epub 2023 May 05
    View PubMed
  26. Gangat N, Kuykendall A, Al Ali N, Goel S, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Komrokji R, Tefferi A. Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival. Blood Adv. 2023 Jun 27; 7 (12):2694-2698
    View PubMed
  27. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Bessonen K, Gangat N, Begna K, Mangaonkar A, Patnaik M, Hogan WJ, Tefferi A, Litzow M, Shah MV, Yi CA, Foran J, Badar T, Alkhateeb HB, Al-Kali A. Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience. Blood Adv. 2023 Apr 25; 7 (8):1351-1355
    View PubMed
  28. Fleti F, Chan O, Singh A, Abdelmagid MG, Al-Kali A, Elliott MA, Begna KH, Foran JM, Badar T, Khera N, Al Ali NH, Padron E, Sallman DA, Shah M, Hiwase D, Pardanani A, Arber DA, Orazi A, Reichard KK, He R, Ketterling RP, Gangat N, Komrokji R, Tefferi A. TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases. Am J Hematol 2023 Apr; 98 (4):E76-E79 Epub 2023 Feb 06
    View PubMed
  29. Hiwase D, Hahn C, Tran ENH, Chhetri R, Baranwal A, Al-Kali A, Sharplin K, Ladon D, Hollins R, Greipp P, Kutyna M, Alkhateeb H, Badar T, Wang P, Ross DM, Singhal D, Shanmuganathan N, Bardy P, Beligaswatte A, Yeung D, Litzow MR, Mangaonkar A, Giri P, Lee C, Yong A, Horvath N, Singhal N, Gowda R, Hogan W, Gangat N, Patnaik M, Begna K, Tiong IS, Wei A, Kumar S, Brown A, Scott H, Thomas D, Kok CH, Tefferi A, Shah MV. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood. 2023 Mar 2; 141 (9):1087-1091
    View PubMed
  30. Al-Kali A, Tibes R, Atherton P, Palmer J, Alkhateeb HB, Patnaik M, Begna K, Gangat N, Hashmi S, He R, Litzow M. A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression. Am J Hematol. 2023 Mar; 98 (3):472-480 Epub 2023 Jan 22
    View PubMed
  31. Gangat N, Begna KH, Al-Kali A, Hogan W, Litzow M, Pardanani A, Tefferi A. Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival. Am J Hematol. 2023 Feb; 98 (2):282-289 Epub 2022 Nov 15
    View PubMed
  32. Gangat N, Begna KH, Al-Kali A, Hogan W, Litzow M, Pardanani A, Tefferi A. Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor. Blood Cancer J. 2023 Jan 4; 13 (1):3 Epub 2023 Jan 04
    View PubMed
  33. Tefferi A, Singh A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Wolanskyj-Spinner A, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Begna KH, Ketterling RP. Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival. Haematologica 2023 Jan 1; 108 (1):245-249 Epub 2023 Jan 01
    View PubMed
  34. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, Litzow M, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms. Ann Hematol 2023 Jan; 102 (1):211-212 Epub 2022 Nov 04
    View PubMed
  35. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, Litzow M, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Autoimmune manifestations in STAG2-mutated myeloid neoplasms. Ann Hematol 2022 Dec; 101 (12):2785-2787 Epub 2022 Oct 03
    View PubMed
  36. Gangat N, Johnson I, McCullough K, Farrukh F, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Tefferi A. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naive acute myeloid leukemia. Haematologica. 2022 Oct 1; 107 (10):2501-2505 Epub 2022 Oct 01
    View PubMed
  37. Tefferi A, Gangat N, Shah M, Alkhateeb H, Patnaik MS, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, Begna KH. Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience. Haematologica. 2022 Oct 1; 107 (10):2474-2479 Epub 2022 Oct 01
    View PubMed
  38. Daver N, Montesinos P, Aribi A, Martinelli G, Altman JK, Wang ES, Roboz GJ, Burke PW, Gaidano G, Walter RB, Thomas X, Jeyakumar D, DeAngelo DJ, Erba HP, Todisco E, Begna K, Advani A, Gastaud L, de la Fuente A, Curti A, Mendez LM, Vyas P, Boissel N, Vey N, Recher C, Longval T, Platzbecker U, Kapp-Schworer S, Schliemann C, Konopleva M, Torres L, Sallman DA, Marcucci G, Marconi G, Kantarjian H, Sloss CM, Malcolm KE, Zweidler-McKay PA, Sweet K. AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions. Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 Suppl 2:S231-S232
    View PubMed
  39. Johnson IM, Bezerra ED, Farrukh F, McCullough K, Al-Kali A, Alkhateeb HB, Begna K, Litzow MR, Hogan WJ, Shah MV, Patnaik MM, Tefferi A, Gangat N. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents. Blood Adv. 2022 Sep 13; 6 (17):5227-5231
    View PubMed
  40. Tefferi A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, DiNardo CD, Kadia TM, Ravandi F, Sasaki K, Begna KH. A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. Am J Hematol. 2022 Sep; 97 (9):1127-1134 Epub 2022 June 30
    View PubMed
  41. Shah MV, Chhetri R, Dholakia R, Kok CH, Gangat N, Alkhateeb HB, Al-Kali A, Patnaik MM, Baranwal A, Greipp PT, He R, Begna KH, Tiong IS, Wei AH, Hiwase D. Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms. Am J Hematol. 2022 Aug; 97 (8):1013-1022 Epub 2022 May 27
    View PubMed
  42. Gangat N, Szuber N, Jadoon Y, Farrukh F, Begna K, Elliott MA, Wolanskyj-Spinner AP, Hanson CA, Pardanani AD, De Stefano V, Barbui T, Vannucchi AM, Tefferi A. 1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events. Blood Adv. 2022 Jul 12; 6 (13):3835-3839
    View PubMed
  43. Shah MV, Mangaonkar AA, Begna KH, Alkhateeb HB, Greipp P, Nanaa A, Elliott MA, Hogan WJ, Litzow MR, McCullough K, Tefferi A, Gangat N, Patnaik MM, Al-Kali A, He R, Chen D. Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood Cancer J. 2022 Jul 8; 12 (7):106 Epub 2022 July 08
    View PubMed
  44. Farrukh F, Chetram D, Al-Kali A, Foran J, Patnaik M, Badar T, Begna K, Hook C, Hogan W, McCullough KB, Mangaonkar A, He R, Gangat N, Tefferi A. Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts. Am J Hematol 2022 Jun 1; 97 (6):E210-E214 Epub 2022 Mar 29
    View PubMed
  45. Mangaonkar AA, Lasho TL, Finke C, Ketterling RP, Reichard KK, McCullough K, Gangat N, Al-Kali A, Begna KH, Hogan WH, Litzow MR, Alkhateeb H, Shah M, Pardanani A, Tefferi A, Al Ali NH, Talati C, Sallman D, Padron E, Komrokji R, Patnaik MM. SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica. 2022 May 1; 107 (5):1189-1192 Epub 2022 May 01
    View PubMed
  46. Singh A, Al-Kali A, Begna KH, Litzow MR, Larsen JT, Sher T, Abdelmagid MG, Farrukh F, Reichard KK, Gangat N, Pardanani A, Tefferi A. Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. Am J Hematol. 2022 May; 97 (5):630-637 Epub 2022 Feb 22
    View PubMed
  47. Begna KH, Xu X, Gangat N, Alkhateeb H, Patnaik MM, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Wolanskyj-Spinner AP, Mangaonkar A, He R, Pardanani A, Shah M, Ketterling RP, Tefferi A. Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3". Blood Cancer J 2022 Apr 7; 12 (4):55 Epub 2022 Apr 07
    View PubMed
  48. Masebo TM, Fikadu BK, Mehari E, Gelaye B, Habte A, Mersha TB, Begna K. The need for rigour and balance in reporting the health impacts of conflict in Tigray, Ethiopia. BMJ Glob Health 2022 Mar; 7 (3)
    View PubMed
  49. Mangaonkar AA, Lasho TL, Ketterling RP, Reichard KK, Gangat N, Al-Kali A, Begna KH, Pardanani A, Al Ali NH, Talati C, Sallman D, Padron E, Patnaik MM, Tefferi A, Komrokji R. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer J. 2022 Feb 1; 12 (2):26 Epub 2022 Feb 01
    View PubMed
  50. Tefferi A, Kittur J, Farrukh F, Begna KH, Patnaik MM, Al-Kali A, Elliott MA, Reichard KK, Gangat N, Pardanani A. Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. Br J Haematol. 2022 Feb; 196 (4):975-983 Epub 2021 Nov 03
    View PubMed
  51. He R, Chiou J, Chiou A, Chen D, Chen CP, Spethman C, Bessonen KR, Oliveira JL, Nguyen PL, Reichard KK, Hoyer JD, Althoff SD, Roh DJ, Miller MA, Yuan J, Olteanu H, Begna K, Tefferi A, Alkhateeb H, Patnaik MM, Litzow MR, Al-Kali A, Viswanatha DS. Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. Blood Cancer J 2022 Jan 25; 12 (1):12
    View PubMed
  52. He R, Chiou J, Chiou A, Chen D, Chen CP, Spethman C, Bessonen KR, Oliveira JL, Nguyen PL, Reichard KK, Hoyer JD, Althoff SD, Roh DJ, Miller MA, Yuan J, Olteanu H, Begna K, Tefferi A, Alkhateeb H, Patnaik MM, Litzow MR, Al-Kali A, Viswanatha DS. Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. Blood Cancer J. 2022 Jan 25; 12(1):12.
    View PubMed
  53. Begna KH, Kittur J, Gangat N, Alkhateeb H, Patnaik MS, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Pardanani A, Hanson CA, Ketterling RP, Tefferi A. European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response. Blood Cancer J. 2022 Jan 17; 12 (1):7
    View PubMed
  54. Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022 Jan 1; 97 (1):68-78 Epub 2021 Nov 09
    View PubMed
  55. Kantarjian HM, Begna KH, Altman JK, Goldberg SL, Sekeres MA, Strickland SA, Arellano ML, Claxton DF, Baer MR, Gautier M, Berman E, Seiter K, Solomon SR, Schiller GJ, Luger SM, Butrym A, Gaidano G, Thomas XG, Montesinos P, Rizzieri DA, Quick DP, Venugopal P, Gaur R, Maness LJ, Kadia TM, Ravandi F, Buyse ME, Chiao JH. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer. 2021 Dec 1; 127 (23):4421-4431 Epub 2021 Aug 23
    View PubMed
  56. Merrell KW, DeWees TA, Osei-Bonsu EB, Acheamfour O, Manirakiza AVC, Avery SM, Mallum AAI, Adjei E, Garda AE, Steiner T, Leavitt T, Lucido J, Ndlovu N, Ngwa W, Ntekim A, Vanderpuye V, Addison ECDK, Woldetsadik ES, Ochieng P Sr, Begna KH. COVID-19 in Sub-Saharan Africa: A Multi-Institutional Survey of the Impact of the Global Pandemic on Cancer Care Resources. Int J Radiat Oncol Biol Phys. 2021 Nov 1; 111 (3S):e349-e350
    View PubMed
  57. Begna KH, Kittur J, Yui J, Gangat N, Patnaik MM, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Wolanskyj AP, Howard MT, Hanson CA, Ketterling RP, Pardanani AD, Tefferi A. De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. Br J Haematol. 2021 Nov; 195 (3):413-416 Epub 2021 Aug 03
    View PubMed
  58. Koster MJ, Kourelis T, Reichard KK, Kermani TA, Beck DB, Cardona DO, Samec MJ, Mangaonkar AA, Begna KH, Hook CC, Oliveira JL, Nasr SH, Tiong BK, Patnaik MM, Burke MM, Michet CJ Jr, Warrington KJ. Clinical Heterogeneity of the VEXAS Syndrome: A Case Series. Mayo Clin Proc. 2021 Oct; 96 (10):2653-2659 Epub 2021 Sept 03
    View PubMed
  59. Venable ER, Chen D, Chen CP, Bessonen KR, Nguyen PL, Oliveira JL, Reichard KK, Hoyer JD, Althoff SD, Roh DJ, Miller MA, Begna K, Patnaik MM, Litzow MR, Al-Kali A, Viswanatha DS, He R. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations. Am J Clin Pathol. 2021 Sep 8; 156 (4):679-690
    View PubMed
  60. Smith CJ, Stewart G, Begna K. 44-Year-Old Man With Fatigue, Weight Loss, and Leukocytosis. Mayo Clin Proc. 2021 Jul; 96 (7):1944-1948
    View PubMed
  61. Gangat N, Guglielmelli P, Szuber N, Begna KH, Patnaik MM, Litzow MR, Al-Kali A, Foran JM, Palmer JM, Alkhateeb H, Elliott MA, Hanson CA, Pardanani A, Mannelli F, Vannucchi AM, Tefferi A. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. Am J Hematol. 2021 Jul 1; 96 (7):781-789 Epub 2021 May 06
    View PubMed
  62. Li M, Binder M, Lasho T, Ferrer A, Gangat N, Al-Kali A, Mangaonkar A, Elliott M, Litzow M, Hogan W, Pardanani A, Wolanskyj-Spinner A, Howard M, King RL, Shah M, Alkhateeb H, Begna K, Tefferi A, Finke C, Oliveira J, Ketterling R, Olteanu H, Patnaik MM. Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. Blood Adv. 2021 Apr 27; 5 (8):2272-2278
    View PubMed
  63. Joshi M, Cook J, McCullough K, Nanaa A, Gangat N, Foran JM, Murthy HS, Kharfan-Dabaja MA, Sproat L, Palmer J, Pardanani A, Tefferi A, Begna K, Elliot M, Al-Kali A, Patnaik M, Shah MV, Hogan WJ, Litzow MR, Alkhateeb HB. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer J 2021 Mar 4; 11 (3):49 Epub 2021 Mar 04
    View PubMed
  64. Begna KH, Ali W, Naseema Gangat Gangat, Elliott MA, Al-Kali A, Litzow MR, Christopher Hook C, Wolanskyj-Spinner AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, Chen D, He R, Viswanatha D, Hanson CA, Ketterling RP, Tefferi A. Mayo Clinic experience with 1123 adults with acute myeloid leukemia. Blood Cancer J. 2021 Mar 2; 11 (3):46 Epub 2021 Mar 02
    View PubMed
  65. Meleveedu KS, Chen D, Nadiminti K, Sidiqi H, Khan S, Alkhateeb H, Shah MV, Patnaik M, Hogan WJ, Begna K, Litzow M. PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia. Leuk Lymphoma 2021 Mar; 62 (3):764-767 Epub 2019 Oct 12
    View PubMed
  66. Liu Q, Major B, Le-Rademacher J, Al-Kali AA, Alkhateeb H, Begna K, Elliott MA, Gangat N, Hogan WJ, Hook CC, Kaufmann SH, Pardanani A, Patnaik MS, Tefferi A, Wolanskyj-Spinner AP, Wei W, Litzow MR. The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study. Blood Lymphat Cancer. 2021; 11:1-9 Epub 2021 Jan 22
    View PubMed
  67. Abu Rmilah AA, Lin G, Begna KH, Friedman PA, Herrmann J. Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. Int J Cancer. 2020 Dec 1; 147 (11):3160-3167 Epub 2020 July 16
    View PubMed
  68. Morsia E, McCullough K, Joshi M, Cook J, Alkhateeb HB, Al-Kali A, Begna K, Elliott M, Hogan W, Litzow M, Shah M, Pardanani A, Patnaik M, Tefferi A, Gangat N. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020 Dec; 95 (12):1511-1521 Epub 2020 Sept 16
    View PubMed
  69. Mangaonkar AA, Reichard KK, Binder M, Coltro G, Lasho TL, Carr RM, Chiu A, Negron V, Hefazi M, Anagnostou T, Timm MM, Hiebert JW, Villasboas JC, Gonsalves WI, Gangat N, Shah M, Alkhateeb HB, Al-Kali A, Elliott MA, Begna KH, Wolanskyj-Spinner AP, Litzow MR, Hogan WJ, Ansell SM, Pardanani A, Tefferi A, Patnaik MM. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood Adv. 2020 Nov 10; 4(21):5425-5430.
    View PubMed
  70. Duong VH, Begna KH, Kashanian S, Sweet K, Wang ES, Caddell R, Shafer DA, Singh ZN, Baer MR, Al-Kali A. Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. Ann Hematol. 2020 Sep; 99 (9):2119-2124 Epub 2020 July 17
    View PubMed
  71. Joshi M, Greipp P, Ball C, Vinod Shah M, Khurana A, Yogarajah M, Nguyen P, He R, Viswanatha D, Jevremovic D, Salama M, Alkhateeb HB, Gangat N, Patnaik M, Begna K, Hogan W, Zblewski D, Litzow M, Al-Kali A. Characteristics of patients with myelodysplastic syndrome with balanced translocations. Br J Haematol. 2020 Jul; 190 (2):244-248 Epub 2020 Mar 17
    View PubMed
  72. Bubik RJ, Barth DM, Hook C, Wolf RC, Muth JM, Mara K, Patnaik MS, Pruthi RK, Marshall AL, Litzow MR, Elliott MA, Hogan WJ, Shah MV, Begna KH, Alkhateeb H, Pardanani A, Ashrani AA, Call TG, Rivera CE, Camoriano JK, Go RS, Wolanskyj-Spinner AP, Parikh SA. Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. Leuk Lymphoma. 2020 Jul; 61 (7):1592-1600 Epub 2020 Mar 11
    View PubMed
  73. Alkharabsheh O, Patnaik MM, Gangat N, Begna KH, Alkhateeb HB, Shah MV, Hogan WJ, He R, Greipp P, Nguyen PL, Litzow MR, Al-Kali A. Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. Ann Hematol. 2020 Mar; 99 (3):513-518 Epub 2020 Jan 23
    View PubMed
  74. He R, Devine DJ, Tu ZJ, Mai M, Chen D, Nguyen PL, Oliveira JL, Hoyer JD, Reichard KK, Ollila PL, Al-Kali A, Tefferi A, Begna KH, Patnaik MM, Alkhateeb H, Viswanatha DS. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Mod Pathol. 2020 Mar; 33 (3):334-343 Epub 2019 Aug 30
    View PubMed
  75. He R, Devine DJ, Tu ZJ, Mai M, Chen D, Nguyen PL, Oliveira JL, Hoyer JD, Reichard KK, Ollila PL, Al-Kali A, Tefferi A, Begna KH, Patnaik MM, Alkhateeb H, Viswanatha DS. Correction to: Hybridization capture-based next-generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. Mod Pathol. 2020 Mar; 33(3):514.
    View PubMed
  76. Anagnostou T, Knudson RA, Pearce KE, Meyer RG, Pitel BA, Peterson JF, Baughn LB, Reichard KK, Ketterling RP, Kloft-Nelson SM, Knutson DL, Khan SP, Gangat N, Litzow MR, Hogan WJ, Wolanskyj A, Al-Kali A, Begna KH, Elliott M, Pardanani A, Foran J, Shah M, Tefferi A, Alkhateeb H, Halling K, Rodriguez V, Greipp PT, Patnaik MM. Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. Am J Hematol 2020 Mar; 95 (3):E68-E72 Epub 2020 Jan 26
    View PubMed
  77. Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, Carr RM, Binder M, Finke CM, Gangat N, Al-Kali A, Begna KH, Reichard KK, Ketterling RP, Al Ali NH, Vafaii P, Zhang L, Padron E, Talati C, Patnaik MM. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia 2020 Feb; 34 (2):656-661 Epub 2019 Sept 11
    View PubMed
  78. Baidoun F, Chen D, Patnaik M, Gangat N, Begna K, Elliott M, Hogan W, Litzow M, Al-Kali A. Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. Leuk Lymphoma. 2019 Oct; 60 (10):2483-2487 Epub 2019 Mar 07
    View PubMed
  79. Al-Kali A, Zblewski D, Foran JM, Patnaik MS, Larrabee BR, Gangat N, Begna KH, Elliott MA, Hogan WJ, Tefferi A, Litzow MR, Go RS. Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. Mayo Clin Proc. 2019 Aug; 94 (8):1467-1474
    View PubMed
  80. Hsieh RW, Ravindran A, Hook CC, Begna KH, Ashrani AA, Pruthi RK, Marshall AL, Hogan W, Litzow M, Hoyer J, Oliveira JL, Vishnu P, Call TG, Al-Kali A, Patnaik M, Gangat N, Pardanani A, Tefferi A, Go RS. Etiologies of Extreme Thrombocytosis: A Contemporary Series. Mayo Clin Proc. 2019 Aug; 94 (8):1542-1550
    View PubMed
  81. Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, Finke C, Begna KH, Elliott MA, Hook CC, Wolanskyj AP, Patnaik MM, Hanson CA, Ketterling RP, Sirhan S, Pardanani A, Gangat N, Busque L, Tefferi A. 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clin Proc. 2019 Apr; 94 (4):599-610 Epub 2019 Feb 26
    View PubMed
  82. Miller KC, Al-Kali A, Shah MV, Hogan WJ, Elliott MA, Begna KH, Gangat N, Patnaik MM, Viswanatha DS, He R, Greipp PT, Sproat LZ, Foran JM, Litzow MR, Alkhateeb HB. Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. Leuk Lymphoma. 2019 Apr; 60 (4):990-999 Epub 2018 Oct 02
    View PubMed
  83. Alkharabsheh OA, Saadeh SS, Zblewski DL, Gangat N, Begna KH, Elliott MA, Alkhateeb HB, Patnaik MS, Hogan WJ, Litzow MR, Al-Kali A. Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. Ann Hematol. 2019 Feb; 98 (2):331-337 Epub 2018 Oct 18
    View PubMed
  84. Vallapureddy RR, Mudireddy M, Penna D, Lasho TL, Finke CM, Hanson CA, Ketterling RP, Begna KH, Gangat N, Pardanani A, Tefferi A. Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. Blood Cancer J. 2019 Jan 25; 9 (2):12
    View PubMed
  85. Park JY, Guo W, Al-Hijji M, El Sabbagh A, Begna KH, Habermann TM, Witzig TE, Lewis BR, Lerman A, Herrmann J. Acute coronary syndromes in patients with active hematologic malignancies - Incidence, management, and outcomes. Int J Cardiol. 2019 Jan 15; 275:6-12 Epub 2018 Oct 05
    View PubMed
  86. Tefferi A, Szuber N, Vallapureddy RR, Begna KH, Patnaik MM, Elliott MA, Hook CC, Christopher Hook C, Wolanskyj AP, Hanson CA, Ketterling RP, Pardanani A, Gangat N. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. Am J Hematol. 2019 Jan; 94 (1):5-9 Epub 2018 Oct 17
    View PubMed
  87. Alkharabsheh O, Saadeh SS, Patnaik MS, Alkhateeb H, Gangat N, Begna KH, Hogan WJ, Greipp PT, He R, Nguyen PL, Litzow MR, Al-Kali A. Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. Am J Hematol 2018 Dec; 93 (12):E398-E401 Epub 2018 Oct 09
    View PubMed
  88. Begna KH, Ali W, Gangat N, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, Chen D, He R, Viswanatha D, Hanson CA, Ketterling RP, Tefferi A. A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. Am J Hematol 2018 Dec; 93 (12):E401-E404 Epub 2018 Oct 17
    View PubMed
  89. Shenoy N, Mudireddy M, Vallapureddy R, Leung N, Pagliaro L, Witzig T, Ou FS, Ordog T, Cheville J, Patnaik M, Thompson RH, Tefferi A, Begna K. Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning? Clin Genitourin Cancer. 2018 Dec; 16 (6):e1117-e1122 Epub 2018 June 28
    View PubMed
  90. Tefferi A, Gangat N, Mudireddy M, Lasho TL, Finke C, Begna KH, Elliott MA, Al-Kali A, Litzow MR, Hook CC, Wolanskyj AP, Hogan WJ, Patnaik MM, Pardanani A, Zblewski DL, He R, Viswanatha D, Hanson CA, Ketterling RP, Tang JL, Chou WC, Lin CC, Tsai CH, Tien HF, Hou HA. Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. Mayo Clin Proc. 2018 Oct; 93 (10):1363-1374 Epub 2018 June 14
    View PubMed
  91. Mangaonkar AA, Gangat N, Al-Kali A, Elliott MA, Begna KH, Hanson CA, Ketterling RP, Wolanskyj-Spinner AP, Hogan WJ, Litzow MR, Patnaik MM. Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. Leuk Res. 2018 Aug; 71:60-62 Epub 2018 July 11
    View PubMed
  92. Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema Gangat Gangat, Pardanani A, Vannucchi AM. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018 Jul; 32 (7):1631-1642 Epub 2018 Mar 23
    View PubMed
  93. Tefferi A, Mudireddy M, Mannelli F, Begna KH, Patnaik MM, Hanson CA, Ketterling RP, Gangat N, Yogarajah M, De Stefano V, Passamonti F, Rosti V, Finazzi MC, Rambaldi A, Bosi A, Guglielmelli P, Pardanani A, Vannucchi AM. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018 May; 32 (5):1200-1210 Epub 2018 Feb 02
    View PubMed
  94. Tefferi A, Nicolosi M, Mudireddy M, Lasho TL, Gangat N, Begna KH, Hanson CA, Ketterling RP, Pardanani A. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia. 2018 May; 32 (5):1189-1199 Epub 2018 Feb 02
    View PubMed
  95. Tefferi A, Barraco D, Lasho TL, Shah S, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Hanson CA, Ketterling RP, Gangat N, Pardanani A. Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood Cancer J. 2018 Mar 7; 8 (3):29 Epub 2018 Mar 07
    View PubMed
  96. Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Szuber N, Begna KH, Patnaik MM, Gangat N, Pardanani A, Tefferi A. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. Blood Adv. 2018 Feb 27; 2 (4):370-380
    View PubMed
  97. Iyer VN, Apala DR, Pannu BS, Kotecha A, Brinjikji W, Leise MD, Kamath PS, Misra S, Begna KH, Cartin-Ceba R, DuBrock HM, Krowka MJ, O'Brien EK, Pruthi RK, Schroeder DR, Swanson KL. Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding. Mayo Clin Proc. 2018 Feb; 93 (2):155-166 Epub 2018 Jan 24
    View PubMed
  98. Larsen CM, Villarraga HR, Begna KH, Litzow MR, Al-Kali A, Herrmann J. Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia. Leuk Lymphoma 2018 Jan; 59 (1):229-232 Epub 2017 June 08
    View PubMed
  99. Alkharabsheh O, Patnaik MM, Gangat N, Begna KH, Alkhateeb HB, Shah MV, Hogan WJ, He R, Greipp P, Nguyen PL, Litzow MR. Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome by the Revised International Prognostic Scoring System Blood. 2018; 132:5510.
  100. Nanah R, McCullough K, Hogan W, Begna K, Patnaik M, Elliott M, Litzow M, Al-Kali A. Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience. Am J Hematol. 2017 Sep; 92 (9):866-871 Epub 2017 June 05
    View PubMed
  101. Saeed L, Patnaik MM, Begna KH, Al-Kali A, Litzow MR, Hanson CA, Ketterling RP, Porrata LF, Pardanani A, Gangat N, Tefferi A. Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. Blood Cancer J. 2017 Mar 31; 7 (3):e550
    View PubMed
  102. Nanah R, Zblewski D, Patnaik MS, Begna K, Ketterling R, Iyer VN, Hogan WJ, Litzow MR, Al-Kali A. Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. Leuk Res. 2016 Nov; 50:112-115 Epub 2016 Oct 03
    View PubMed
  103. Begna K, Abdelatif A, Schwager S, Hanson C, Pardanani A, Tefferi A. Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience. Blood Cancer J 2016 May 27; 6:e427
    View PubMed
  104. Barraco D, Elala YC, Lasho TL, Begna KH, Gangat N, Finke C, Hanson CA, Ketterling RP, Pardanani A, Tefferi A. Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. Blood Cancer J 2016 Apr 8; 6:e415 Epub 2016 Apr 08
    View PubMed
  105. Gangat N, Patnaik MM, Begna K, Al-Kali A, Litzow MR, Ketterling RP, Hanson CA, Pardanani AD, Tefferi A. Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. Blood Cancer J 2016 Apr 8; 6:e414 Epub 2016 Apr 08
    View PubMed
  106. Tefferi A, Al-Kali A, Begna KH, Patnaik MM, Lasho TL, Rizo A, Wan Y, Hanson CA. Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. Blood Cancer J 2016 Mar 11; 6:e405
    View PubMed
  107. Jawad MD, Go RS, Ketterling RP, Begna KH, Reichard KK, Shi M. Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report. Clin Case Rep. 2016 Mar; 4 (3):282-6 Epub 2016 Feb 08
    View PubMed
  108. Gangat N, Patnaik MM, Begna K, Kourelis T, Al-Kali A, Elliott MA, Hogan WJ, Letendre L, Litzow MR, Knudson RA, Ketterling RP, Hodnefield JM, Hanson CA, Pardanani AD, Tefferi A. Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. Mayo Clin Proc. 2015 Dec; 90 (12):1623-38 Epub 2015 Nov 03
    View PubMed
  109. Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM, Laborde RR, Wassie E, Schimek L, Hanson CA, Gangat N, Wang X, Pardanani A. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. N Engl J Med. 2015 Sep 3; 373 (10):908-19
    View PubMed
  110. Abdelrahman RA, Begna KH, Al-Kali A, Hogan WJ, Litzow MR, Pardanani A, Tefferi A. Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. Br J Haematol. 2015 Apr; 169 (1):77-80 Epub 2014 Dec 15
    View PubMed
  111. Alsahlawi A, Alkhateeb H, Patnaik M, Begna K, Elliott M, Hogan WJ, Litzow M, Al-Kali A. Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):e39-41. Epub 2014 Jun 10.
    View PubMed
  112. DeAngelo DJ, Mesa RA, Fiskus W, Tefferi A, Paley C, Wadleigh M, Ritchie EK, Snyder DS, Begna K, Ganguly S, Ondovik MS, Rine J, Bhalla KN. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol. 2013 Aug; 162(3):326-35. Epub 2013 May 23.
    View PubMed
  113. Gangat N, Patnaik MM, Begna K, Kourelis T, Knudson RA, Ketterling RP, Hodnefield JM, Hanson CA, Pardanani A, Tefferi A. Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. Am J Hematol. 2013 Aug; 88(8):690-3. Epub 2013 Jun 20.
    View PubMed
  114. Lim MY, Al-Kali A, Ashrani AA, Begna KH, Elliott MA, Hogan WJ, Hook CC, Kaufmann SH, Letendre L, Litzow MR, Patnaik MS, Pardanani A, Tefferi A, Wolanskyj AP, Grill DE, Pruthi RK. Comparison of complication rates of Hickman((R)) catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy. Leuk Lymphoma. 2013 Jun; 54 (6):1263-7 Epub 2012 Nov 19
    View PubMed
  115. Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, Hogan WJ, Litzow MR, Leontovich A, Kowalski M, Tefferi A. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013 Jun; 27 (6):1322-7 Epub 2013 Mar 05
    View PubMed
  116. Chen D, Bachanova V, Ketterling RP, Begna KH, Hanson CA, Viswanatha DS. A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease. Am J Surg Pathol. 2013 Jan; 37: (1)147-51.
    View PubMed
  117. Reddy CG, Mauermann ML, Solomon BM, Ringler MD, Jerath NU, Begna KH, Amrami KK, Spinner RJ. Neuroleukemiosis: an unusual cause of peripheral neuropathy. Leuk Lymphoma. 2012 Dec; 53 (12):2405-11 Epub 2012 May 28
    View PubMed
  118. Pardanani A, Finke C, Lasho TL, Al-Kali A, Begna KH, Hanson CA, Tefferi A. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia. 2012 Apr; 26 (4):693-9 Epub 2011 Sept 13
    View PubMed
  119. Elliott MA, Letendre L, Tefferi A, Hogan WJ, Hook C, Kaufmann SH, Pruthi RK, Pardanani A, Begna KH, Ashrani AA, Wolanskyj AP, Al-Kali A, Litzow MR. Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy. Eur J Haematol. 2012 Mar; 88(3):237-43. Epub 2011 Nov 17.
    View PubMed
  120. Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, Begna KH, Al-Kali A, Ketterling RP, Hanson CA, Pardanani A. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012 Jan; 87 (1):25-33
    View PubMed
  121. Begna KH, Pardanani A, Mesa R, Litzow MR, Hogan WJ, Hanson CA, Tefferi A. Long-term outcome of pomalidomide therapy in myelofibrosis. Am J Hematol. 2012 Jan; 87(1):66-8. Epub 2011 Nov 12.
    View PubMed
  122. Tefferi A, Jimma T, Gangat N, Vaidya R, Begna KH, Hanson CA, Van Dyke DL, Caramazza D, Pardanani A. Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. Blood. 2011 Oct 27; 118 (17):4595-8 Epub 2011 Aug 31
    View PubMed
  123. Vaidya R, Caramazza D, Begna KH, Gangat N, Van Dyke DL, Hanson CA, Pardanani A, Tefferi A. Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival. Blood. 2011 May 26; 117 (21):5612-5 Epub 2011 Mar 30
    View PubMed
  124. Pardanani A, Begna K, Finke C, Lasho T, Tefferi A. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. Am J Hematol. 2011 Apr; 86: (4)343-5.
    View PubMed
  125. Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia. 2011 Feb; 25(2):301-4. Epub 2010 Nov 05.
    View PubMed
  126. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011 Feb 1; 29 (4):392-7 Epub 2010 Dec 13
    View PubMed
  127. Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke, Hanson C, Pardanani A, Tefferi A. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011 Jan; 25(1):82-8. Epub 2010 Oct 14.
    View PubMed
  128. Caramazza D, Hussein K, Siragusa S, Pardanani A, Knudson RA, Ketterling RP, Tefferi A. Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations. Eur J Haematol. 2010 Mar; 84(3):191-200. Epub 2009 Nov 30.
    View PubMed
  129. Hussein K, Pardanani AD, Van Dyke DL, Hanson CA, Tefferi A. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010 Jan 21; 115 (3):496-9 Epub 2009 Nov 09
    View PubMed
  130. Tefferi A, Siragusa S, Hussein K, Schwager SM, Hanson CA, Pardanani A, Cervantes F, Passamonti F. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype. Am J Hematol. 2010 Jan; 85(1):14-7.
    View PubMed
  131. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, Elliott MA, Litzow MR, Hanson CA, Pardanani A. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia. 2010 Jan; 24(1):105-9. Epub 2009 Oct 22.
    View PubMed
  132. Vaidya R, Siragusa S, Huang J, Schwager SM, Hanson CA, Hussein K, Pardanani A, Tefferi A. Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years. Mayo Clin Proc. 2009 Dec; 84 (12):1114-9
    View PubMed
  133. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009 Sep; 33 (9):1199-203 Epub 2009 Feb 27
    View PubMed
  134. Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur J Haematol. 2009 May; 82(5):329-38. Epub 2009 Jan 9
    View PubMed
  135. Tefferi A, Mesa RA, Pardanani A, Hussein K, Schwager S, Hanson CA, Steensma DP. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol. 2009 May; 84 (5):265-7
    View PubMed
  136. Hussein K, Huang J, Lasho T, Pardanani A, Mesa RA, Williamson CM, Ketterling RP, Hanson CA, Van Dyke DL, Tefferi A. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis. Eur J Haematol. 2009 Apr; 82(4):255-9. Epub 2008 Feb 10
    View PubMed
  137. Hussein K, Ketterling RP, Dewald GW, Van Dyke DL, Mesa R, Hanson CA, Tefferi A. Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studies. Leuk Res. 2008 Oct; 32(10):1597-600. Epub 2008 Feb 1
    View PubMed
  138. Hussein K, Jahagirdar B, Gupta P, Burns L, Larsen K, Weisdorf D. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia. Am J Hematol. 2008 Jun; 83(6):446-50.
    View PubMed
  139. Hussein K, Ketterling RP, Hulshizer RL, Kuffel DG, Wiktor AE, Hanson CA, Tefferi A, Van Dyke DL. Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis. Eur J Haematol. 2008 Apr; 80(4):318-21. Epub 2007 Dec 18
    View PubMed
  140. Pardanani A, Lasho TL, Hussein K, Schwager SM, Finke CM, Pruthi RK, Tefferi A. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc. 2008 Apr; 83(4):457-9.
    View PubMed
  141. Hussein K, Ketterling R, Hulschizer R, Kuffel D, Wiktor A, Hanson C, Tefferi A, VanDyke D. Peripheral blood cytogenetic studies in Hematological Neoplasms: Predictors of Obtaining Metaphases for Analysis European Journal of Hematology. 2007 Dec.
  142. Coxon RE, Fekade D, Knox K, Hussein K, Melka A, Daniel A, Griffin GG, Warrell DA. The effect of antibody against TNF alpha on cytokine response in Jarisch-Herxheimer reactions of louse-borne relapsing fever. QJM. 1997 Mar; 90(3):213-21.
  143. Fekade D, Knox K, Hussein K, Melka A, Lalloo DG, Coxon RE, Warrell DA. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med. 1996 Aug 1; 335(5):311-5.
    View PubMed
PST-20224125